Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axim Biotechnologies (OP: AXIM )

0.4300 USD +0.0100 (+2.38%)
Official Closing Price Updated: 3:57 PM EST, Dec 3, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 139,169
Open 0.4400
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.4200
Today's Range 0.4100 - 0.4549
52wk Range 0.1000 - 1.440
Shares Outstanding 56,736,450
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application
From GlobeNewswire News Releases
AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
From GlobeNewswire News Releases

Performance

YTD
-4.44%
-4.44%
1 Month
-10.42%
-10.42%
3 Month
-34.73%
-34.73%
6 Month
-0.05%
-0.05%
1 Year
-2.27%
-2.27%

More News

Read More
AXIM® Biotechnologies Issues Update Letter to Shareholders
From GlobeNewswire News Releases
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
From GlobeNewswire News Releases
Medical Marijuana, Inc. Investment Company AXIM Biotechnologies Files Patent for Worlds First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
From NewMediaWire
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing
From GlobeNewswire News Releases
AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19
From GlobeNewswire News Releases
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
From GlobeNewswire News Releases
AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies
From GlobeNewswire News Releases
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
From GlobeNewswire News Releases
Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.